Insider · CIK 0001579824

BAUM CHARLES M

Reports to the SEC for 7 companies · WATERTOWN, MA

sec.gov

Transactions

Companies

Filings

CIK

0001579824

Forms 4 and 5

Insider transactions

50 trades

Date	Company	Role	Code	Shares	Price	Value	Shares after
2026-06-17	ACRVAcrivon Therapeutics, Inc. · Stock Option (Right to Buy)A Award	Director	AAward	+20.3K sh	—	—	20,275
2026-06-04	PMVPPMV Pharmaceuticals, Inc. · Stock Option (right to buy)A Award	Director	AAward	+42K sh	—	—	42,000
2026-05-18	ACRVAcrivon Therapeutics, Inc.A Award	Director	AAward	+9,366 sh	—	—	9,366
2025-06-13	ACRVAcrivon Therapeutics, Inc. · Stock Option (Right to Buy)A Award	Director	AAward	+20.3K sh	—	—	20,275
2025-06-05	PMVPPMV Pharmaceuticals, Inc. · Stock Option (right to buy)A Award	Director	AAward	+33.5K sh	—	—	33,500
2025-01-08	Poseida Therapeutics, Inc.Stock Option (Right to Buy)D Disposition to Issuer	Director	DDisposition to Issuer	−27.4K sh	—	—	0
2025-01-08	Poseida Therapeutics, Inc.U Disposition from Tender	Director	UDisposition from Tender	−78.6K sh	—	—	0
2025-01-08	Poseida Therapeutics, Inc.Stock Option (Right to Buy)D Disposition to Issuer	Director	DDisposition to Issuer	−57K sh	—	—	0
2025-01-08	Poseida Therapeutics, Inc.Stock Option (Right to Buy)D Disposition to Issuer	Director	DDisposition to Issuer	−27.4K sh	—	—	0
2024-06-20	ACRVAcrivon Therapeutics, Inc. · Stock Option (Right to Buy)A Award	Director	AAward	+20.3K sh	—	—	20,275
2024-06-17	Poseida Therapeutics, Inc.A Award	Director	AAward	+19.7K sh	—	—	78,600
2024-06-17	Poseida Therapeutics, Inc.Stock Option (Right to buy)A Award	Director	AAward	+27.4K sh	—	—	27,350
2024-06-06	PMVPPMV Pharmaceuticals, Inc. · Stock Option (right to buy)A Award	Director	AAward	+67.5K sh	—	—	67,500
2024-01-23	Mirati Therapeutics, Inc.Option to Purchase Common StockD Disposition to Issuer	Director, Founder, President, and CEO	DDisposition to Issuer	−100K sh	—	—	0
2024-01-23	Mirati Therapeutics, Inc.Option to Purchase Common StockD Disposition to Issuer	Director, Founder, President, and CEO	DDisposition to Issuer	−112K sh	—	—	0
2024-01-23	Mirati Therapeutics, Inc.Option to Purchase Common StockD Disposition to Issuer	Director, Founder, President, and CEO	DDisposition to Issuer	−81.5K sh	—	—	0
2024-01-23	Mirati Therapeutics, Inc.D Disposition to Issuer	Director, Founder, President, and CEO	DDisposition to Issuer	−20.4K sh	—	—	0
2024-01-23	Mirati Therapeutics, Inc.D Disposition to Issuer	Director, Founder, President, and CEO	DDisposition to Issuer	−123K sh	—	—	114,482
2024-01-23	Mirati Therapeutics, Inc.Option to Purchase Common StockD Disposition to Issuer	Director, Founder, President, and CEO	DDisposition to Issuer	−178K sh	—	—	0
2024-01-23	Mirati Therapeutics, Inc.Option to Purchase Common StockD Disposition to Issuer	Director, Founder, President, and CEO	DDisposition to Issuer	−69.3K sh	—	—	0
2024-01-23	Mirati Therapeutics, Inc.Option to Purchase Common StockD Disposition to Issuer	Director, Founder, President, and CEO	DDisposition to Issuer	−168K sh	—	—	0
2024-01-23	Mirati Therapeutics, Inc.D Disposition to Issuer	Director, Founder, President, and CEO	DDisposition to Issuer	−94.1K sh	—	—	20,425
2024-01-23	Mirati Therapeutics, Inc.Option to Purchase Common StockD Disposition to Issuer	Director, Founder, President, and CEO	DDisposition to Issuer	−1,559 sh	—	—	0
2024-01-23	Mirati Therapeutics, Inc.Option to Purchase Common StockD Disposition to Issuer	Director, Founder, President, and CEO	DDisposition to Issuer	−7,520 sh	—	—	0
2023-12-29	Mirati Therapeutics, Inc.A Award	Director, Founder, President, and CEO	AAward	+20.4K sh	$58.75	+$1.2M	247,700
2023-08-09	Mirati Therapeutics, Inc.A Award	Director, Founder, President, and CEO	AAward	+54.1K sh	$37.00	+$2M	227,275
2023-06-22	ACRVAcrivon Therapeutics, Inc. · Stock Option (Right to Buy)A Award	Director	AAward	+32.5K sh	—	—	32,500
2023-06-15	Poseida Therapeutics, Inc.Stock Option (Right to buy)A Award	Director	AAward	+27.4K sh	—	—	27,350
2023-06-15	Poseida Therapeutics, Inc.A Award	Director	AAward	+19.7K sh	—	—	58,950
2023-06-08	PMVPPMV Pharmaceuticals, Inc. · Stock Option (right to buy)A Award	Director	AAward	+21.5K sh	—	—	21,500
2023-01-20	Mirati Therapeutics, Inc.Employee Stock Option (Right to Buy)A Award	Director, Founder, President, and CEO	AAward	+7,520 sh	—	—	7,520
2023-01-20	Mirati Therapeutics, Inc.A Award	Director, Founder, President, and CEO	AAward	+4,444 sh	—	—	173,221
2023-01-04	Mirati Therapeutics, Inc.S Sale	Director, Founder, President, and CEO	SSale	−3,648 sh	$46.60	−$170K	168,777
2022-12-21	Mirati Therapeutics, Inc.S Sale	Director, Founder, President, and CEO	SSale	−9,092 sh	$40.42	−$367K	172,425
2022-12-19	Mirati Therapeutics, Inc.A Award	Director, Founder, President, and CEO	AAward	+53.6K sh	—	—	181,517
2022-11-28	Mirati Therapeutics, Inc.Employee Stock Option (Right to Buy)M Exercise/Conversion	Director, Founder, President, and CEO	MExercise/Conversion	−69.3K sh	—	—	69,258
2022-11-28	Mirati Therapeutics, Inc.S Sale	Director, Founder, President, and CEO	SSale	−69.3K sh	$100.00	−$6.93M	127,899
2022-11-28	Mirati Therapeutics, Inc.M Exercise/Conversion	Director, Founder, President, and CEO	MExercise/Conversion	+69.3K sh	$17.41	+$1.21M	197,155
2022-06-16	Poseida Therapeutics, Inc.Stock Option (Right to Buy)A Award	Director	AAward	+57K sh	—	—	57,000
2022-06-16	Poseida Therapeutics, Inc.A Award	Director	AAward	+39.3K sh	—	—	39,300
2022-06-02	PMVPPMV Pharmaceuticals, Inc. · Stock Option (right to buy)A Award	Director	AAward	+19.5K sh	—	—	19,500
2022-01-18	Mirati Therapeutics, Inc.Employee Stock Option (Right to Buy)M Exercise/Conversion	Director, Founder, President, and CEO	MExercise/Conversion	−3,703 sh	—	—	178,052
2022-01-18	Mirati Therapeutics, Inc.S Sale	Director, Founder, President, and CEO	SSale	−2,517 sh	$120.48	−$303K	127,899
2022-01-18	Mirati Therapeutics, Inc.M Exercise/Conversion	Director, Founder, President, and CEO	MExercise/Conversion	+3,703 sh	$27.00	+$100K	130,416
2022-01-14	Mirati Therapeutics, Inc.Employee Stock Option (Right to Buy)A Award	Director, Founder, President, and CEO	AAward	+42.3K sh	—	—	42,325
2022-01-14	Mirati Therapeutics, Inc.A Award	Director, Founder, President, and CEO	AAward	+25.5K sh	—	—	126,713
2022-01-04	Mirati Therapeutics, Inc.S Sale	Director, Founder, President, and CEO	SSale	−69 sh	$149.09	−$10.3K	101,170
2022-01-04	Mirati Therapeutics, Inc.S Sale	Director, Founder, President, and CEO	SSale	−4,045 sh	$147.73	−$598K	101,239
2021-12-16	Mirati Therapeutics, Inc.G Gift	Director, Founder, President, and CEO	GGift	−7,430 sh	—	—	105,284
2021-12-03	Mirati Therapeutics, Inc.Employee Stock Option (Right to Buy)M Exercise/Conversion	Director, Founder, President, and CEO	MExercise/Conversion	−47.2K sh	—	—	0

Recent filings

Accepted (ET)
Jun 224
BAUM CHARLES M0000905148-26-003024
SEC(opens sec.gov)
Jun 54
BAUM CHARLES M0001579824-26-000003
SEC(opens sec.gov)
May 204
BAUM CHARLES M0000905148-26-002557
SEC(opens sec.gov)
Jun 174
BAUM CHARLES M0000905148-25-002170
SEC(opens sec.gov)
Jun 94
BAUM CHARLES M0001415889-25-016254
SEC(opens sec.gov)
Jan 84
BAUM CHARLES M0001415889-25-001085
SEC(opens sec.gov)
Jun 244
BAUM CHARLES M0000905148-24-001774
SEC(opens sec.gov)
Jun 184
BAUM CHARLES M0000950170-24-074864
SEC(opens sec.gov)
Jun 104
BAUM CHARLES M0001415889-24-016199
SEC(opens sec.gov)
Jan 234
BAUM CHARLES M0001140361-24-003528
SEC(opens sec.gov)

Companies

Address

C/O ACRIVON THERAPEUTICS, INC. 480 ARSENAL WAY, SUITE 100

WATERTOWN, MA, 02472